Genomic Urine Test Enables Non-Invasive Detection of Bladder and Other Urinary Tract Cancers

The five-year survival rate for individuals with bladder cancer is 77% compared to the general population; however, this rate increases to 96% if the tumor has not spread beyond the bladder wall lining. The disease's prevalence and the significance of early detection make prompt testing essential for individuals experiencing blood in urine or other symptoms. A set of non-invasive genomic urine tests can now efficiently and accurately detect or rule out bladder cancer by measuring five biomarker genes at the molecular level.

Pacific Edge Ltd.’s (Dunedin City, New Zealand) Cxbladder is a family of non-invasive genomic urine tests designed for detecting and managing bladder cancer. The tests combine clinical risk factors with gene expression markers to rapidly and accurately determine the presence or absence of bladder cancer. The Cxbladder suite comprises the Cxbladder Detect, Cxbladder Triage, Cxbladder Resolve, and Cxbladder Monitor tests.

Cxbladder Detect facilitates non-invasive detection of bladder and other urinary tract cancers using a small urine sample from patients. It offers clinicians a rapid, cost-effective, and accurate means of determining cancer presence as a useful adjunct to cystoscopy. Cxbladder Triage combines genomic biomarkers with phenotypic and clinical risk factors to accurately identify patients with hematuria who have a low probability of bladder cancer, potentially eliminating the need for more extensive urological evaluation. Cxbladder Triage is a tool for clinicians and physicians in the primary evaluation of patients with hematuria, aiming to reduce the requirement for costly and invasive work-ups in patients with a low likelihood of urothelial carcinoma.

Cxbladder Resolve detects patients likely to have aggressive or advanced bladder cancer. Used as part of the primary evaluation of hematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), Cxbladder Resolve assists clinicians in accurately identifying patients with a high probability of having high-grade or late-stage bladder cancer. Such patients may need alternative or expedited treatment options or prioritization for further investigation in high throughput settings. Cxbladder Monitor enables urologists to track bladder cancer patients for disease recurrence and accurately identifies patients with a prior history of urothelial cancer (UC) who have a low probability of recurrent urothelial carcinoma based on their Cxbladder Monitor score. It is intended to be used as the preferred adjunct test to cystoscopy in managing patients for ongoing evaluation of recurrent bladder cancer.

Related Links:
Pacific Edge Ltd.